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The failure of chemotherapy is an important problem in treating non-resectable or recurrent non-small-cell lung cancer (NSCLC) (Williams. 1989) . NSCLC uusually shows intrinsic multidrug resistance. whereas small-cell lung cancer (SCLC) initially responds well to various anti-cancer agents (Bergh et al.. 1990) . Advanced NSCLCs are generally treated by therapeutic protocols using cisplatin. vinca alkaloids (vindesine (VDS) . vincristine (VCR) and etoposide (VP-16)) (Dhingra et al.. 1985 : Britran et al.. 1988 : Richards et al.. 1991 .
Several types of drug resistance to anti-cancer agents have been characterised in human carcinoma cell lines in *itro (Fojo et al.. 1985 : Gros et al.. 1986 : Giaccone et al.. 1992 ). The selection of cells which are resistant to lipophilic compounds (anthracyclines. vinca alkaloids. podophyllotoxins and colchicine) results in the development of cross-resistance or multidrug resistance to other related drugs (Chen et al.. 1986 : Roninson. 1991 . The classical form of multidrug resistance in human cancer is due to increased activitv of the P-glvcoprotein (P-Gp) encoded by the human multidrug resistance zene 1 (MDRI) (Ueda et al.. 1987) . Previously. we reported no apparent correlation between the level of VDRI expression and clinical prognosis in NSCLC. whereas a number of adenocarcinomas expressed high levels of MDRI as shown by reverse transcription-polymerase chain reaction (RT-PCR) assay (Abe et al.. 1994a) .
Recently. the multidrug resistance-associated protein (MRP) gene was cloned (Cole et al.. 1992) . and its expression was shown to be related to multidrug resistance in a non-P-Gpmediated multidrug-resistant small-cell lung cancer cell line. Direct evidence for the function of the MRP gene has been obtained in a multidrug-resistant cell line transfected with this gene (Grant et al.. 1994 
Materials and methods
Patients and tumours One hundred and four fresh NSCLC tumour specimens and ten specimens of adjacent normal lung tissues were obtained with informed consent at surgical resection from previously untreated patients. Tissues were rapidly frozen and stored at -80'C until analyses. The tumour specimens were not contaminated by normal lung tissues. Total cellular RNA was prepared from the frozen specimens by standard procedures (Sambrook et al.. 1989 (Figure 1) . Nineteen (18.3%) of 104 NSCLC specimens showed high-level (+ +) expression of the MRP gene. and 14 (13.4%) showed a moderate level (+) (Figure 2) .
Ten normal lung tissue specimens showed no apparent expression of the MRP gene. Three tumour specimens (two adenocarcinomas and one squamous cell carcinoma) showed increased levels of MRP gene expression as compared with the corresponding normal lung tissue. The other seven tumour specimens showed no apparent increase in level of MRP gene expression (data not shown). NSCLCs and normal tissues were subclassified into three grades according to the ratio of the MRP P-actin expression: (+ +). more than 0.06; (+), 0.01-0.06: (-) Figure  5 ). Nine of 20 patients with MRP-expressing squamous cell carcinomas who received post-operative chemotherapy showed lower survival rates than the 11 patients with non-or low-MRP-expressing squamous cell carcinoma (P<0.01, Figure 6 ). However, the patients with MRP-expressing adenocarcinoma did not show a significantly worse prognosis than those whose tumour tissue was negative or showed low levels of MRP expression (Figure 7 ). (FHens et al., 1994) , and such studies are now in progress in our laboratory.
We also examined levels of MDR] expression in the 104 NSCLCs. MRP was first described as a molecule related to multidrug resistance in a non-P-Gp-mediated multidrug-resistant smallcell lung cancer (Cole et al., 1992) . The results of the present study suggest the predominant clinical relevance of MRP gene expression in the multidrug resistance phenomenon of NSCLC. Many studies have demonstrated atypical non-PGp-mediated multidrug resistance in lung cancer (Slovak et al., 1988; Cole et al., 1989; Baas et al., 1990; Reeve et al., 1990; Versantvoort et al., 1992; Nieuwint et al., 1992) . This study strongly supports the concept that MRP is a major molecule involved in the atypical non-P-Gp-mediated multidrug resistance in NSCLC.
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